---
title: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
nct_id: NCT05317494
overall_status: RECRUITING
sponsor: AbbVie
study_type: OBSERVATIONAL
primary_condition: Acute Myeloid Leukemia
countries: Greece
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05317494.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05317494"
ct_last_update_post_date: 2025-07-16
last_seen_at: "2026-05-12T07:07:24.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece

**Official Title:** A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece

**NCT ID:** [NCT05317494](https://clinicaltrials.gov/study/NCT05317494)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** AbbVie
- **Conditions:** Acute Myeloid Leukemia
- **Start Date:** 2022-05-26
- **Completion Date:** 2026-12
- **CT.gov Last Update:** 2025-07-16

## Brief Summary

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Greece.

Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled.

Around 100 participants will be enrolled in the study in approximately 15 sites in Greece.

Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 30 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 30 months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Participant diagnosed Acute Myeloid Leukemia (AML) who is ineligible to intensive chemotherapy and is eligible to receive venetoclax as a first-line therapy, as per Greek Ministry of Health (MOH) label.
* Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.

Exclusion Criteria:

\- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
```

## Arms

- **Venetoclax Participants** — Participants treated with Venetoclax in accordance with approved local label.

## Primary Outcomes

- **Percentage of Participants Achieving Overall Survival (OS)** _(time frame: Up to 30 Months)_ — OS is defined as the time from treatment initiation to death from any cause.

## Secondary Outcomes

- **Percentage of Participants Achieving Composite Complete Remission** _(time frame: Up to 30 Months)_
- **Total Time of Treatment with Venetoclax Combination Therapy** _(time frame: Up to 30 Months)_
- **Time to Transfusion Independence** _(time frame: Up to 30 Months)_
- **Post Baseline RBC and Platelet Transfusion Independence Rate** _(time frame: Up to 30 Months)_
- **Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Considered Minimally Clinical Important** _(time frame: Up to 30 Months)_
- **Treatment Patterns Venetoclax in Combination with Hypomethylating Agents (HMAs)** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Number of Transfusions (Red Blood Cell [RBC] or Platelets) Received during First-line Treatment in an Outpatient Setting** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Number of Hospitalizations during First-line Treatment** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Number of Intensive Care Unit (ICU) Admissions during First-line Treatment** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Number of Visits in a Private Healthcare Practitioner** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Name of Relevant Medication due to Infections (Antibiotics or Other)** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Dosing Scheme of Relevant Medication due to Infections (Antibiotics or Other)** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Number of Laboratory Tests** _(time frame: Up to 30 Months)_
- **Healthcare Resource Utilization as the Type of Laboratory Tests** _(time frame: Up to 30 Months)_

## Locations (13)

- Olympion General Clinic /ID# 268392, Pátrai, Achaia, Greece — _ACTIVE_NOT_RECRUITING_
- General Hospital of Athens Gennimatas /ID# 245968, Athens, Attica, Greece — _ACTIVE_NOT_RECRUITING_
- General Hospital of Athens Laiko /ID# 244338, Athens, Attica, Greece — _ACTIVE_NOT_RECRUITING_
- University General Hospital Attikon /ID# 248265, Athens, Attica, Greece — _ACTIVE_NOT_RECRUITING_
- University General Hospital of Heraklion PA.G.N.I /ID# 244337, Heraklion, Crete, Greece — _COMPLETED_
- General University Hospital of Alexandroupolis /ID# 244235, Alexandroupoli, Greece — _ACTIVE_NOT_RECRUITING_
- General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 244339, Athens, Greece — _ACTIVE_NOT_RECRUITING_
- General Anti-cancer Hospital Agios Savvas /ID# 244408, Athens, Greece — _ACTIVE_NOT_RECRUITING_
- General Hospital of Athens Laiko - Hematology Location /ID# 244234, Athens, Greece — _ACTIVE_NOT_RECRUITING_
- University General Hospital of Ioannina /ID# 244336, Ioannina, Greece — _ACTIVE_NOT_RECRUITING_
- University General Hospital of Patras /ID# 244335, RION Patras Achaia, Greece — _COMPLETED_
- Papageorgiou General Hospital /ID# 248266, Thessaloniki, Greece — _RECRUITING_
- General Hospital of Thessaloniki George Papanikolaou /ID# 244237, Thessaloniki, Greece — _ACTIVE_NOT_RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.olympion general clinic /id# 268392|pátrai|achaia|greece` — added _(2026-05-12)_
- `locations.general hospital of athens gennimatas /id# 245968|athens|attica|greece` — added _(2026-05-12)_
- `locations.general hospital of athens laiko /id# 244338|athens|attica|greece` — added _(2026-05-12)_
- `locations.university general hospital attikon /id# 248265|athens|attica|greece` — added _(2026-05-12)_
- `locations.university general hospital of heraklion pa.g.n.i /id# 244337|heraklion|crete|greece` — added _(2026-05-12)_
- `locations.general university hospital of alexandroupolis /id# 244235|alexandroupoli||greece` — added _(2026-05-12)_
- `locations.general hospital of athens evaggelismos and ophthalmiatrio of athens polyclinic /id# 244339|athens||greece` — added _(2026-05-12)_
- `locations.general anti-cancer hospital agios savvas /id# 244408|athens||greece` — added _(2026-05-12)_
- `locations.general hospital of athens laiko - hematology location /id# 244234|athens||greece` — added _(2026-05-12)_
- `locations.university general hospital of ioannina /id# 244336|ioannina||greece` — added _(2026-05-12)_
- `locations.university general hospital of patras /id# 244335|rion patras achaia||greece` — added _(2026-05-12)_
- `locations.papageorgiou general hospital /id# 248266|thessaloniki||greece` — added _(2026-05-12)_
- `locations.general hospital of thessaloniki george papanikolaou /id# 244237|thessaloniki||greece` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05317494.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05317494*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*